4/17
08:48 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $170.00 to $150.00. They now have a "hold" rating on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $170.00 to $150.00. They now have a "hold" rating on the stock.
4/17
08:14 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Bank of America Co. from $575.00 to $547.00. They now have an "underperform" rating on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Bank of America Co. from $575.00 to $547.00. They now have an "underperform" rating on the stock.
4/17
07:37 am
regn
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications [Yahoo! Finance]
Low
Report
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications [Yahoo! Finance]
4/17
07:00 am
regn
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
Low
Report
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
4/15
08:25 am
regn
Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S. [Yahoo! Finance]
Low
Report
Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S. [Yahoo! Finance]
4/14
02:22 pm
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $1,019.00 to $917.00. They now have a "buy" rating on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $1,019.00 to $917.00. They now have a "buy" rating on the stock.
4/14
05:40 am
regn
Reflecting On Immuno-Oncology Stocks' Q4 Earnings: Regeneron (NASDAQ:REGN) [Yahoo! Finance]
Low
Report
Reflecting On Immuno-Oncology Stocks' Q4 Earnings: Regeneron (NASDAQ:REGN) [Yahoo! Finance]
4/6
08:15 am
regn
Regeneron Pharmaceuticals (NasdaqGS:REGN) Drops 10% Over Last Week Despite Dupixent Approval in Japan [Yahoo! Finance]
Low
Report
Regeneron Pharmaceuticals (NasdaqGS:REGN) Drops 10% Over Last Week Despite Dupixent Approval in Japan [Yahoo! Finance]
4/5
06:11 am
regn
3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years [Yahoo! Finance]
Low
Report
3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years [Yahoo! Finance]
3/31
04:17 pm
regn
Intellia Focuses on Pipeline Development Amid Stiff Competition [Yahoo! Finance]
Low
Report
Intellia Focuses on Pipeline Development Amid Stiff Competition [Yahoo! Finance]
3/31
10:45 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at JPMorgan Chase & Co. from $1,100.00 to $1,000.00. They now have an "overweight" rating on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at JPMorgan Chase & Co. from $1,100.00 to $1,000.00. They now have an "overweight" rating on the stock.
3/29
09:26 pm
regn
Sources: White House ordered firing of L.A. federal prosecutor on ex-Fatburger CEO case [Los Angeles Times (CA)]
Low
Report
Sources: White House ordered firing of L.A. federal prosecutor on ex-Fatburger CEO case [Los Angeles Times (CA)]
3/28
02:13 am
regn
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD) [Yahoo! Finance]
Low
Report
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD) [Yahoo! Finance]
3/28
02:00 am
regn
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Low
Report
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
3/25
04:05 pm
regn
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
Low
Report
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
3/21
06:46 am
regn
3 Reasons to Sell REGN and 1 Stock to Buy Instead [Yahoo! Finance]
Low
Report
3 Reasons to Sell REGN and 1 Stock to Buy Instead [Yahoo! Finance]
3/18
05:48 am
regn
Regeneron Pharmaceuticals (REGN): Among the Best Biotech Stocks to Buy According to Billionaires [Yahoo! Finance]
Low
Report
Regeneron Pharmaceuticals (REGN): Among the Best Biotech Stocks to Buy According to Billionaires [Yahoo! Finance]
3/17
10:07 am
regn
2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off [Yahoo! Finance]
Low
Report
2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off [Yahoo! Finance]
3/11
10:58 pm
regn
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem [Yahoo! Finance]
Medium
Report
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem [Yahoo! Finance]
3/11
10:50 pm
regn
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
Medium
Report
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
3/11
09:35 pm
regn
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem [Yahoo! Finance]
Medium
Report
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem [Yahoo! Finance]
3/11
09:32 pm
regn
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
Medium
Report
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
3/11
07:12 pm
regn
Cramer's Lightning Round: ‘We're going to stay away from' Sirius XM [CNBC]
Medium
Report
Cramer's Lightning Round: ‘We're going to stay away from' Sirius XM [CNBC]
3/11
10:26 am
regn
Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript [Seeking Alpha]
Low
Report
Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript [Seeking Alpha]
3/10
06:15 pm
regn
Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts [Yahoo! Finance]
Medium
Report
Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts [Yahoo! Finance]